Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO-MCBS Scorecards

ESMO MCBS  1000x150

The ESMO-MCBS Scorecards provides a centralised location of cancer medicines that have been scored and published by ESMO.

It includes all cancer medicines approved by the European Medicines Agency (from January 2016) and the US Food and Drug Administration (from January 2020).

Number of studies
Non-curative setting
5 17
4 84
3 119
2 31
1 18
Curative setting
A 34
C 2
ESMO-MCBS Scores by tumour type
Non-curative setting
Breast Cancer 28
Central Nervous System Malignancies 0
Endocrine Tumours 19
Gastrointestinal Cancers 43
Genitourinary Cancers 49
Gynaecological Malignancies 28
Head and neck cancer 6
Refractory NTRK fusion–positive cancers 2
Sarcoma 10
Skin Cancers 20
Thoracic Malignancies 64
Curative setting
Breast Cancer 6
Central Nervous System Malignancies 1
Endocrine Tumours 0
Gastrointestinal Cancers 15
Genitourinary Cancers 2
Gynaecological Malignancies 0
Head and neck cancer 0
Refractory NTRK fusion–positive cancers 0
Sarcoma 2
Skin Cancers 8
Thoracic Malignancies 2

The ESMO-MCBS Scorecards

The ESMO-MCBS Scorecards allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.

Tested Agent(s) Combined Agent(s) Control Arm Treatment Setting Tumour Type Tumour Sub-type Tumour Sub-group Tumour Stage Score Ref. Scorecard
T-DM1 - Lapatinib + capecitabine Previously received trastuzumab and a taxane (extensive crossover) Breast Cancer Breast Cancer HER2+ Unresectable locally advanced or metastatic
Pertuzumab Trastuzumab + docetaxel Trastuzumab + docetaxel + placebo No prior anti-HER2 therapy or ChT for metastatic disease Breast Cancer Breast Cancer HER2+ Locally recurrent unresectable or metastatic
Trastuzumab Lapatinib Lapatinib After progression on prior trastuzumab + ChT regimen(s) Breast Cancer Breast Cancer HER2+ HR- Metastatic
Palbociclib Fulvestrant Fulvestrant + placebo 2nd line treatment Breast Cancer Breast Cancer HR+ HER2- Locally advanced or metastatic
Panitumumab FOLFOX4 (5-fluorouracil, leucovorin, and oxaliplatin) FOLFOX4 (5-fluorouracil, leucovorin, and oxaliplatin) 1st line metastatic colorectal cancer (post hoc KRAS, NRAS BRAF WT) Gastrointestinal Cancers Colon and Rectal Cancer - Metastatic
Cetuximab FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) 1st line metastatic (post hoc KRAS, NRAS WT) Gastrointestinal Cancers Colon and Rectal Cancer RAS-WT Metastatic
Cetuximab - Best supportive care Refractory metastatic KRAS-WT Gastrointestinal Cancers Colon and Rectal Cancer KRAS-WT Metastatic
Bevacizumab Chemotherapy Paclitaxel or topotecan or liposomal doxorubicin Recurrent platinum-resistant ovarian cancer Gynaecological Malignancies Ovarian Cancer - Metastatic
Erlotinib - Carboplatin gemcitabine 1st line stage III or IV non-squamous, with EGFR mutation Thoracic Malignancies Non-small-cell Lung Cancer EGFR+ Metastatic
Erlotinib - Platinum-based chemotherapy doublet 1st line stage III or IV non-squamous, with EGFR mutation Thoracic Malignancies Non-small-cell Lung Cancer EGFR+ Metastatic

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.